Patents by Inventor Markus Rudolph

Markus Rudolph has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS
    Publication number: 20200199155
    Abstract: Compounds of formula (I) wherein R1, R2, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Daniel HUNZIKER, Jerome HERT, Holger KUEHNE, Patrizio MATTEI, Markus RUDOLPH
  • Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
    Patent number: 10669285
    Abstract: Compounds of formula (I) wherein R1, R2, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: June 2, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Daniel Hunziker, Jerome Hert, Holger Kuehne, Patrizio Mattei, Markus Rudolph
  • Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
    Patent number: 10654857
    Abstract: Compounds of formula (I) wherein R1, R2, A, W, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: May 19, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Holger Kuehne, Patrizio Mattei, Markus Rudolph
  • Bicyclic compounds as dual ATX/CA inhibitors
    Patent number: 10647719
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 12, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • Phenoxymethyl derivatives
    Patent number: 10640472
    Abstract: The invention provides novel compounds having the general formula (I) wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: May 5, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Holger Kuehne, Thomas Luebbers, Rainer E. Martin, Patrizio Mattei, Werner Neidhart, Hans Richter, Markus Rudolph, Emmanuel Pinard
  • GLUCOSE DEHYDROGENASE VARIANTS WITH IMPROVED PROPERTIES
    Publication number: 20200087633
    Abstract: The present invention relates to improved variants of variants of the Glucose Dehydrogenases (GlucDH) derived from Bacillus subtilis having improved properties in the presence of cNAD as cofactor, to genes encoding such variant GlucDHs, to proteins of such GlucDH variants, and to different applications of these GlucDH variants, particularly for determining concentrations of sugars, especially of glucose, in samples such as bodily fluids, especially blood.
    Type: Application
    Filed: December 22, 2017
    Publication date: March 19, 2020
    Applicant: Roche Diabetes Care, Inc.
    Inventors: Mara Boenitz-Dulat, Carina Horn, Peter Kratzsch, Thomas Meier, Markus Rudolph, Bernd Schneidinger
  • BICYCLIC COMPOUNDS AS ATX INHIBITORS
    Publication number: 20200087307
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 19, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrizio Mattei, Jerome Hert, Daniel Hunziker, Markus Rudolph, Petra Schmitz, Patrick Di Giorgio
  • NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS
    Publication number: 20200079779
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 12, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz
  • HETEROCYCLIC COMPOUNDS USEFUL AS DUAL ATX/CA INHIBITORS
    Publication number: 20200002297
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, X, W, m and n are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 12, 2019
    Publication date: January 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrizio MATTEI, Jérôme HERT, Daniel HUNZIKER, Markus RUDOLPH, Petra SCHMITZ, Patrick DI GIORGIO, Justin GOMME
  • BICYCLIC COMPOUNDS AS ATX INHIBITORS
    Publication number: 20200002336
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, A, X, m and n are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 12, 2019
    Publication date: January 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jérôme HERT, Daniel HUNZIKER, Patrizio MATTEI, Markus RUDOLPH, Petra SCHMITZ, Patrick DI GIORGIO
  • Triaza-spirodecanones as DDR1 inhibitors
    Patent number: 10435407
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: October 8, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Buelent Kocer, Bernd Kuhn, Marco Prunotto, Hans Richter, Martin Ritter, Markus Rudolph, Alexander Lee Satz
  • NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS
    Publication number: 20190185426
    Abstract: The invention provides novel compounds having the general formula (I) wherein R2, R3, R4, R5, R6, R7, R8, X, A and R11 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 20, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Benoit HORNSPERGER, Hans Peter MAERKI, Peter MOHR, Michael REUTLINGER, Markus RUDOLPH
  • DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS
    Publication number: 20190185427
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X and R11 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 20, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Benoit Hornsperger, Hans P. Maerki, Peter Mohr, Michael Reutlinger, Markus Rudolph
  • TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS
    Publication number: 20190169189
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: BERND BUETTELMANN, BUELENT KOCER, BERND KUHN, MARCO PRUNOTTO, HANS RICHTER, MARTIN RITTER, MARKUS RUDOLPH, ALEXANDER LEE SATZ
  • NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRAl INHIBITORS
    Publication number: 20190152895
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R3, R8, R9, R10 and R11 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 23, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hans P. MAERKI, Benoit HORNSPERGER, Peter MOHR, Michael REUTLINGER, Markus RUDOLPH
  • BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS
    Publication number: 20190144457
    Abstract: Compounds of formula (I) wherein R1, R2, A, W, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 16, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Holger Kuehne, Patrizio Mattei, Markus Rudolph
  • ORAL ADMINISTRATION FORM COMPRISING PROBIOTIC BACTERIA
    Publication number: 20190110997
    Abstract: The invention relates to an oral administration form which comprises at least one species of probiotic microorganisms, where it itself and/or the probiotic bacteria is/are provided with a coating which comprises at least two cellulose ethers.
    Type: Application
    Filed: November 16, 2018
    Publication date: April 18, 2019
    Applicant: Merck Patent GmbH
    Inventors: Markus RUDOLPH, Stefan HENKE, Iris MANNECK
  • Triaza-spirodecanones as DDR1 inhibitors
    Patent number: 10239876
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 26, 2019
    Assignee: Hoffman La-Roche Inc.
    Inventors: Bernd Buettelmann, Buelent Kocer, Bernd Kuhn, Marco Prunotto, Hans Richter, Martin Ritter, Markus Rudolph, Alexander Lee Satz
  • NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS
    Publication number: 20180312515
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 23, 2018
    Publication date: November 1, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrizio Mattei, Jerome Hert, Daniel Hunziker, Markus Rudolph, Petra Schmitz, Patrick Di Giorgio
  • OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL
    Publication number: 20180280352
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, Y and R2 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 4, 2018
    Publication date: October 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrizio Mattei, Daniel Hunziker, Patrick Di Giorgio, Jerome Hert, Markus Rudolph, Lisha Wang